Source comparison
BPC-157 for Neuropathy Research: Study Comparison
Rat sciatic crush injury (2018) 10 mcg/kg daily IP × 28 days Motor function recovery score +38% at day 28 Single-center study, no mechanistic pathway confirmation beyond GAP-43 Strongest evidence for structural regeneration but dose far exceeds human-equivalen
This comparison does not assign a generated winner or score.
- Rat sciatic crush injury (2018)
- 10 mcg/kg daily IP × 28 days
- Motor function recovery score
- +38% at day 28
- Single-center study, no mechanistic pathway confirmation beyond GAP-43
- Strongest evidence for structural regeneration but dose far exceeds human-equivalent scaling
- Streptozotocin diabetic neuropathy model (2020)
- 10 mcg/kg daily IP × 21 days
- Mechanical allodynia threshold
- +29% pain threshold increase
- No nerve fiber density improvement. Symptomatic relief only
- Suggests analgesic effect without addressing underlying axonal loss
- Oxaliplatin CIPN prevention (2021)
- 10 mcg/kg daily IP concurrent with chemo
- Sensory nerve action potential amplitude
- +18% preservation vs chemo alone
- Preventive protocol, not post-injury treatment; no recovery data
- Cannot extrapolate to therapeutic use after neuropathy is established
- In vitro dorsal root ganglion culture (2019)
- 1–100 ng/mL in culture medium
- Neurite outgrowth length
- +52% at 100 ng/mL
- Cell culture doesn't replicate in vivo inflammatory environment
- Confirms direct neurotrophic activity but dosing irrelevant to systemic use